Moderna stock jumps after Q1 revenue triples and loss narrows
Updated
Updated · Barron's · May 1
Moderna stock jumps after Q1 revenue triples and loss narrows
17 articles · Updated · Barron's · May 1
Revenue rose to $389 million from $108 million, with $311 million from international sales, while shares gained 7.5% in premarket trading.
The company posted a $1.34 billion loss, or $3.40 a share, better than expected, after cutting research and administrative costs despite a roughly $900 million litigation settlement charge.
The settlement resolved a patent dispute with Arbutus Biopharma and Genevant Sciences, and Moderna maintained its 2026 goal of up to 10% revenue growth and a return to sales growth.
Could Moderna's record-breaking patent settlement change how biopharma companies approach innovation, licensing, and risk management for future vaccines?
With global vaccine access still delayed in many countries, how might this settlement influence the speed and equity of new medicine distribution worldwide?